ArticleBlood advances2026
Comutation of asxl1 and IDH2R172K enhances leukemogenesis and correlates with epigenetic activation of MAPK and AP-1 in zebrafish.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractComutations of addition of sex combs-like 1 (asxl1) and isocitrate dehydrogenases 2 (IDH2) are associated with aggressive acute myeloid leukemia (AML), yet the underlying mechanisms have remained poorly understood. We generated a zebrafish model combining an asxl1 mutation and an IDH2R172K mutation that recapitulates the clinicopathological and molecular features of high-risk AML with differentiation blockade and reduced animal survival. The double mutants exhibited promoter hypermethylation, downregulation of tet2 expression, and global changes in methylation profiles. Genes pertaining to MAPK and activator protein-1 (AP-1) pathways were upregulated, which was associated with reduced NAD phosphate oxidase expression and an increase in reactive oxygen species (ROS). Single-cell RNA sequencing confirmed differentiation arrest in hematopoietic stem and progenitor cells, with activation of MAPK and AP-1 signaling. The double mutants showed resistance to the IDH2 inhibitor but were sensitive to ROS or DNA methylation targeting. In silico analysis of gene expression in human AML carrying comutation of ASXL1/IDH2 also showed activation of the MAPK and AP-1 pathways. Our findings underscore an epigenetic-metabolic signaling circuit driving leukemogenesis and reveal novel therapeutic strategies for this AML subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.